The present disclosure provides compositions intended for the prophylaxis or the treatment of disorders related to GHLO infections in pets, the compositions are prepared using at least one strain of lactic bacteria and/or one of its metabolites or a medium fermented by at least one lactic bacteria that has been isolated and selected for its ability to display a strong anti-Helicobacter bactericidal activity in vitro.